COVID-19: Panacea Biotec, RDIF to start Sputnik V production in India
COVID-19: Panacea Biotec, RDIF to start Sputnik V production in India RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V. File photo Updated: May 24, 2021, 05:46 PM IST Panacea Biotec, one of India's largest pharmaceutical companies and the Russian Direct Investment Fund (RDIF) of Russia have taken a major decision to increase the production of coronavirus vaccine in the country. The two companies have announced that they will produce 100 million doses of 100 million Russian Sputnik V every year. In a statement, Panacea Biotec Ltd (PB...